文献速递妇科

高危子宫内膜癌分子分型包括L1CAM表达的预后和治疗意义

Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2024-11-16

该回顾性队列研究纳入2006年1月1日至2017年12月31日奥斯陆大学医院妇科肿瘤科收治的489例高危子宫内膜癌患者,按ProMisE进行分子分型并检测L1CAM表达。多变量分析中ProMisE对复发时间(TTR)显著但对癌症特异性生存(CSS)不显著,L1CAM对两者均显著;ProMisE与L1CAM同模型时ProMisE失去显著性而L1CAM保持显著。结论认为L1CAM是p53异常组和NSMP组的额外不良因素,这些组在强化辅助治疗的研究中需特别关注。

要点

  • 489例中486例可分子分型:POLE突变37例(8%)、MMRd 148例(30%)、p53异常189例(39%)、NSMP 112例(23%)。
  • L1CAM高表达256例(53%),低表达227例(46%),缺失6例(1%)。
  • 多变量分析中ProMisE对TTR显著但对CSS不显著,L1CAM对TTR和CSS均显著。

核心结论

  • L1CAM是p53异常组和NSMP组的额外不良因素,这些组在强化辅助治疗的研究中需特别关注。

研究设计与样本

  • 回顾性队列研究,纳入2006年1月1日至2017年12月31日奥斯陆大学医院妇科肿瘤科收治的患者,共489例,其中486例可进行分子分型。
  • 按ProMisE进行分子分型并检测L1CAM表达,主要结局为复发时间(TTR)和癌症特异性生存(CSS)。

主要发现

  • 489例中486例可分子分型:POLE突变37例(8%),MMRd 148例(30%),p53异常189例(39%),NSMP 112例(23%)。
  • L1CAM高表达256例(53%),低表达227例(46%),缺失6例(1%)。
  • 多变量分析中ProMisE对TTR显著但对CSS不显著,L1CAM对TTR和CSS均显著。
  • ProMisE与L1CAM在同一多变量模型时,ProMisE失去显著性而L1CAM保持显著。
  • POLE突变肿瘤预后极好,p53异常或L1CAM过表达肿瘤预后差且远处复发频率高;MMRd、NSMP及L1CAM低的p53异常肿瘤预后居中。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of molecular classification and L1CAM in high-risk endometrial cancer is uncertain. We aimed to determine the association of molecular profiling and L1CAM with patterns of relapse and survival. MATERIAL AND METHODS: This retrospective cohort study included patients referred to Department for Gynecologic Oncology, Oslo University Hospital between January 1, 2006 and December 31, 2017. L1CAM expression and molecular profiling according to ProMisE was performed. Main outcome was time to recurrence (TTR) and cancer specific survival (CSS). RESULTS: Of 489 patients, 486 could be molecular classified. Thirty-seven (8 %) had POLE mutated tumors, 148 (30 %) had MMRd tumors, 189 (39 %) had p53 abnormal tumors, and 112 (23 %) had NSMP tumors. High L1CAM expression was observed in 256 (53 %), low in 227 (46 %) tumors (6 (1 %) missing). ProMisE was significant for TTR but not for CSS in multivariable analysis. L1CAM was significant in multivariable analysis for both TTR and CSS. In a multivariable model with ProMisE and L1CAM expression in the same multivariable model, ProMisE lost significance while L1CAM remained significant. Patients with POLE mutated tumors entailed an excellent prognosis while patients with p53 abnormal or L1CAM overexpressing tumors entailed a poor prognosis with a high frequency of distant recurrences. Patients with MMRd tumors, NSMP and p53 abnormal tumors with low L1CAM had an intermediate prognosis. CONCLUSIONS: L1CAM is an additional adverse factor in the p53 abnormal and NSMP groups. These groups need special attention in studies intensifying adjuvant treatment.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kleppe A, Lindemann K, Kildal W, et al. Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer. Gynecol Oncol. 2024. PMID: 39549540. doi:10.1016/j.ygyno.2024.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。